A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction - PubMed (original) (raw)

Randomized Controlled Trial

A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction

Hari K Parthasarathy et al. Eur J Heart Fail. 2009 Oct.

Abstract

Aims: To determine whether valsartan improves treadmill exercise time, in patients with symptomatic heart failure with a preserved ejection fraction (HFPEF), compared with placebo.

Methods and results: In this multicentred, double-blind, 14-week study, patients were randomized to receive valsartan (V) 80 mg or placebo (P) once daily on top of background medications. The dose of valsartan was force-titrated up to 320 mg. A total of 152 patients were randomized (V = 70, P = 82). Most patients had well-controlled hypertension (V = 91.2%, P = 89.0%) (mean baseline systolic BP approximately 130 mmHg) and >50% were receiving an angiotensin-converting enzyme inhibitor and/or beta-blocker (V = 57.4%, P = 54.9%). The mean ejection fraction at baseline was 70.48% in the placebo group (n = 64) and 71.52% in the valsartan group (n = 79). Valsartan had no significant effect on exercise time (primary variable), gas exchange variables, 6 min walk test distance, exertion-related symptoms, brain natriuretic peptide levels, echocardiographic parameters, or quality-of-life scores. Valsartan significantly lowered peak exercise systolic BP (-13.1 mmHg vs. placebo; P < 0.001) and improved ratings of perceived exertion (Borg score) (-0.69 vs. placebo; P = 0.008).

Conclusion: In this population, which predominantly included patients with well-controlled hypertension and symptomatic HFPEF, addition of valsartan did not increase exercise time within 14 weeks. However, valsartan 320 mg reduced blood pressure and improved symptoms of perceived exertion (Borg score) during exercise and was generally well-tolerated.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Patient disposition.

Figure 2

Figure 2

Least-squares mean changes from baseline to endpoint in (A) maximum systolic blood pressure (SBP) and maximum diastolic blood pressure (DBP) and (B) maximum Borg score. Error bars denote standard error of the mean. *P < 0.001 vs. placebo; †P = 0.008 vs. placebo.

Similar articles

Cited by

References

    1. Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med. 2004;351:1097–1105. - PubMed
    1. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47:320–332. - PubMed
    1. MacFadyen RJ, MacLeod CM, Shiels P, Russell Smith W, MacDonald TM. Isolated diastolic heart failure as a cause of breathlessness in the community. the Arbroath study. Eur J Heart Fail. 2001;3:243–248. - PubMed
    1. Chinnaiyan KM, Alexander D, Maddens M, McCullough PA. Curriculum in cardiology:integrated diagnosis and management of diastolic heart failure. Am Heart J. 2007;153:189–200. - PubMed
    1. Aurigemma GP. Diastolic heart failure–a common and lethal condition by any name. N Engl J Med. 2006;355:308–310. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources